The Role of Inflammasomes in Heart Failure

Heart failure (HF) poses a significant world health challenge due to the increase in the aging population and advancements in cardiac care. In the pathophysiology of HF, the inflammasome has been correlated with the development, progression, and complications of HF disease. Discovering biomarkers linked to inflammasomes enhances understanding of HF diagnosis and prognosis. Directing inflammasome signaling emerges as an innovative therapeutic strategy for managing HF. The present review aims to delve into this inflammatory cascade, understanding its role in the development of HF, its potential role as biomarker, as well as the prospects of modulating inflammasomes as a therapeutic approach for HF.

[1]  M. D. de Borst,et al.  Increased interleukin-6 is associated with higher risk of heart failure in people with type 2 diabetes. , 2024, ESC heart failure.

[2]  C. Jonasson,et al.  Association of inflammatory markers with incident heart failure or cancer in the HUNT3 and Health ABC population studies. , 2024, European journal of preventive cardiology.

[3]  F. Vasques-Nóvoa,et al.  Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study. , 2024, Atherosclerosis.

[4]  Xiao-cheng Cheng,et al.  NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction. , 2023, Life sciences.

[5]  A. Manolis,et al.  Neurohumoral Activation in Heart Failure , 2023, International journal of molecular sciences.

[6]  D. Tousoulis,et al.  Inflammasomes in Atherosclerosis—From Pathophysiology to Treatment , 2023, Pharmaceuticals.

[7]  P. Ridker,et al.  Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction. , 2023, JACC. Heart failure.

[8]  J. Coresh,et al.  Association of Interleukin-6 and Interleukin-18 with Cardiovascular Disease in Older Adults: Atherosclerosis Risk in Communities Study. , 2023, European journal of preventive cardiology.

[9]  I. Mourouzis,et al.  SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century? , 2023, Nutrients.

[10]  J. McMurray,et al.  Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction , 2023, Circulation. Heart failure.

[11]  Gang Liu,et al.  Burden, Trends, and Inequalities of Heart Failure Globally, 1990 to 2019: A Secondary Analysis Based on the Global Burden of Disease 2019 Study , 2023, Journal of the American Heart Association.

[12]  S. Prabhu,et al.  Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation , 2023, Circulation research.

[13]  A. von Eckardstein,et al.  Quantifying inflammation using interleukin‐6 for improved phenotyping and risk stratification in acute heart failure , 2023, European journal of heart failure.

[14]  Shan Liu,et al.  The selective NLRP3 inflammasome inhibitor MCC950 improves isoproterenol-induced cardiac dysfunction by inhibiting cardiomyocyte senescence. , 2022, European journal of pharmacology.

[15]  A. Leite-Moreira,et al.  Interleukin-6, infection and cardiovascular outcomes in acute heart failure: Findings from the EDIFICA registry. , 2022, Cytokine.

[16]  Yuting Feng,et al.  Colchicine Ameliorates Dilated Cardiomyopathy Via SIRT2‐Mediated Suppression of NLRP3 Inflammasome Activation , 2022, Journal of the American Heart Association.

[17]  L. Kang,et al.  Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction. , 2022, European journal of pharmacology.

[18]  Jianfang Liu,et al.  MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice , 2022, Frontiers in Cardiovascular Medicine.

[19]  E. Roselló-Lletí,et al.  Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models , 2022, International journal of molecular sciences.

[20]  Liyuan Zhu,et al.  Emerging Roles of Inflammasomes in Cardiovascular Diseases , 2022, Frontiers in Immunology.

[21]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[22]  F. Yang,et al.  MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure , 2022, Bioengineered.

[23]  P. Aukrust,et al.  Targeting the Inflammasome in Cardiovascular Disease , 2021, JACC. Basic to translational science.

[24]  Han Xiao,et al.  The Role of the Inflammasome in Heart Failure , 2021, Frontiers in Physiology.

[25]  P. Secchiero,et al.  Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity , 2021, International journal of molecular sciences.

[26]  Jianfang Liu,et al.  Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation. , 2021, International immunopharmacology.

[27]  Z. Giricz,et al.  AIM2-driven inflammasome activation in heart failure. , 2021, Cardiovascular research.

[28]  A. Abbate,et al.  Preservation of Contractile Reserve and Diastolic Function by Inhibiting the NLRP3 Inflammasome with OLT1177® (Dapansutrile) in a Mouse Model of Severe Ischemic Cardiomyopathy Due to Non-Reperfused Anterior Wall Myocardial Infarction , 2021, Molecules.

[29]  Hua Zhu,et al.  Gasdermin D in pyroptosis , 2021, Acta pharmaceutica Sinica. B.

[30]  Ming Xu,et al.  Membrane nanotubes facilitate the propagation of inflammatory injury in the heart upon overactivation of the β-adrenergic receptor , 2020, Cell Death & Disease.

[31]  J. Canada,et al.  Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure , 2020, Journal of cardiovascular pharmacology.

[32]  Zhi-Sheng Jiang,et al.  Emerging roles of absent in melanoma 2 in cardiovascular diseases. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[33]  S. Nattel,et al.  Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation , 2020, Circulation research.

[34]  Shiqi Yang,et al.  Pyroptosis: a pro-inflammatory type of cell death in cardiovascular disease. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[35]  B. V. Van Tassell,et al.  Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease , 2020, Circulation research.

[36]  Jia Hu,et al.  NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy , 2020, Redox biology.

[37]  C. McCarthy,et al.  Inflammation in Heart Failure: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[38]  Xiao-yu Liu,et al.  Blockade of β-adrenergic signaling suppresses inflammasome and alleviates cardiac fibrosis. , 2020, Annals of translational medicine.

[39]  D. Mann,et al.  Reappraising the role of inflammation in heart failure , 2020, Nature Reviews Cardiology.

[40]  Hongshan Chen,et al.  SNO-MLP (S-Nitrosylation of Muscle LIM Protein) Facilitates Myocardial Hypertrophy Through TLR3 (Toll-Like Receptor 3)–Mediated RIP3 (Receptor-Interacting Protein Kinase 3) and NLRP3 (NOD-Like Receptor Pyrin Domain Containing 3) Inflammasome Activation , 2020, Circulation.

[41]  Lei Xu,et al.  The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. , 2019, International immunopharmacology.

[42]  C. Ferrario,et al.  NLRP3 inhibition improves heart function in GPER knockout mice. , 2019, Biochemical and biophysical research communications.

[43]  J. Ting,et al.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics , 2019, Nature Reviews Immunology.

[44]  Antoni Bayes-Genis,et al.  The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. , 2019, Journal of the American College of Cardiology.

[45]  Jinyu Pan,et al.  AIM2 gene silencing attenuates diabetic cardiomyopathy in type 2 diabetic rat model , 2019, Life sciences.

[46]  S. Miyamoto,et al.  Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca2+/Calmodulin-Dependent Protein Kinase II &dgr; Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling , 2018, Circulation.

[47]  Corey L. Reynolds,et al.  Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation , 2018, Circulation.

[48]  S. Nasoohi,et al.  MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury. , 2018, Journal of neurotrauma.

[49]  K. Otsu,et al.  Mitochondria and sterile inflammation in the heart , 2018 .

[50]  D. Tousoulis,et al.  The Role of Colchicine in Pericardial Syndromes. , 2018, Current pharmaceutical design.

[51]  S. Ylä-Herttuala,et al.  Aggravated Postinfarct Heart Failure in Type 2 Diabetes Is Associated with Impaired Mitophagy and Exaggerated Inflammasome Activation. , 2017, The American journal of pathology.

[52]  J. Bauersachs,et al.  Immune mechanisms in heart failure , 2017, European journal of heart failure.

[53]  F. Roubille,et al.  Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model. , 2017, International journal of cardiology.

[54]  J. Butler,et al.  ASC Methylation and Interleukin-1&bgr; Are Associated with Aerobic Capacity in Heart Failure , 2017, Medicine and science in sports and exercise.

[55]  M. Ishii,et al.  Colchicine Improves Survival, Left Ventricular Remodeling, and Chronic Cardiac Function After Acute Myocardial Infarction. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[56]  Dacheng Wang,et al.  Pore-forming activity and structural autoinhibition of the gasdermin family , 2016, Nature.

[57]  Jagmeet P. Singh,et al.  Inflammatory Mediators and Clinical Outcome in Patients With Advanced Heart Failure Receiving Cardiac Resynchronization Therapy. , 2016, The American journal of cardiology.

[58]  Si Ming Man,et al.  Regulation of inflammasome activation , 2015, Immunological reviews.

[59]  Sky W. Brubaker,et al.  Innate immune pattern recognition: a cell biological perspective. , 2015, Annual review of immunology.

[60]  Wei Wu,et al.  A meta-analysis of proinflammatory cytokines in chronic heart failure , 2014, Heart Asia.

[61]  M. Cleman,et al.  Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. , 2014, JACC. Heart failure.

[62]  Fan Wang,et al.  Association of nucleotide-binding oligomerization domain-like receptor 3 inflammasome and adverse clinical outcomes in patients with idiopathic dilated cardiomyopathy , 2013, Clinical chemistry and laboratory medicine.

[63]  N. Frangogiannis,et al.  The pathogenesis of cardiac fibrosis , 2013, Cellular and Molecular Life Sciences.

[64]  S. Bunn,et al.  Cytokine Interactions with Adrenal Medullary Chromaffin Cells , 2010, Cellular and Molecular Neurobiology.

[65]  S. Anker,et al.  Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. , 2009, Heart failure clinics.

[66]  H. Shimokawa,et al.  Colchicine, a microtubule depolymerizing agent, inhibits myocardial apoptosis in rats. , 2007, The Tohoku journal of experimental medicine.

[67]  H. Okamura,et al.  Increased circulating interleukin-18 in patients with congestive heart failure , 2002, Heart.

[68]  M. Yamaoka-Tojo,et al.  Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. , 2002, Journal of cardiac failure.

[69]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[70]  D. Grobbee,et al.  An epidemic of heart failure? Recent evidence from Europe. , 1998, European heart journal.

[71]  G. P. V. van Hout,et al.  The Inflammasomes in Cardiovascular Disease. , 2018, Experientia supplementum.

[72]  W. Gao,et al.  IL-18 cleavage triggers cardiac inflammation and fibrosis upon &bgr;-adrenergic insult , 2018, European heart journal.

[73]  B. Borlaug.  Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[74]  C. H. Conrad,et al.  Direct effects of colchicine on myocardial function: studies in hypertrophied and failing spontaneously hypertensive rats. , 1999, Hypertension.

[75]  G. Bonsel,et al.  Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. , 1994, American journal of public health.